Recent Biotech Funding, Deals and Partnerships

2,235 views

Published on

Nearly one out of every 8 dollars invested in companies are invested in biotech. Biotech investment has increased significantly in the past few years, and 2013 saw a notable spike. In the last few years, this has resulted in a complex series of deals and transactions, ranging from complete buyouts, to licensing transactions, to a variety of collaborative arrangements. In addition to this influx of corporate capital, biotechnology companies have seen a significant influx of venture capital, as investors invest in new science and technology that they believe have potential in the clinic. This Kalorama Information report, Recent Biotech Funding Deals and Partnerships, attempts to provide clarity on the phenomenon. The report analyzes the recent, current and potential landscape for investing in the biotechnology sector. Included in the report's coverage are the following data points 56 Key Biotech Deals Analyzed: Financial Details and Therapeutic Potential Venture Capital Dollar Trends, Overall Dollars Invested 2009-2013 (in US billions) Health Care as a Percentage of Total Venture Investment, 2009-2012 (in US billions) Biotech Companies Raising Series A Dollars, 2009-2012, Greater than $2 Million Number of Biotech Series A Companies by Indication Oncology, Platform Discovery, Diagnostics, CNS, Autoimmune) Biotech Total Deal Value, 2005-2012 IPO Statistics Personalized Medicine Disclosed M&A Number of Deals by Focus, 2010-2013 Analyzed are both venture and corporate capital funding efforts. In addition, the report looks at other collaborative approaches, including licensing, joint ventures and partnerships aimed at moving product candidates into the market place as approved therapies, especially if they address unmet medical needs. This report also reviews the nature and direction of funding trends, and reviews the important role that investments play in moving technology into the market place. The report profiles several biotechnology sector companies and the deals that they were involved in from 2011 to 2014. Some of the companies and transactions profiled in the report include: Alkermes, Boston Biomedical, Dicerna Pharmaceuticals, immatics biotechnologies, Micromet, Reata Pharmaceuticals, UCB and Xoma.The information presented in this report is the result of data gathered from company product literature and other corporate brochures and documents, as well as information found in the scientific and trade press. In addition, interviews were conducted with executives and analysts.

Published in: Economy & Finance, Business
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
2,235
On SlideShare
0
From Embeds
0
Number of Embeds
2
Actions
Shares
0
Downloads
0
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Recent Biotech Funding, Deals and Partnerships

  1. 1. ReportLinker Find Industry reports, Company profiles and Market Statistics >> Get this Report Now by email! Recent Biotech Funding, Deals and Partnerships Published on May 2014 Report Summary Nearly one out of every 8 dollars invested in companies are invested in biotech. Biotech investment has increased significantly in the past few years, and 2013 saw a notable spike. In the last few years, this has resulted in a complex series of deals and transactions, ranging from complete buyouts, to licensing transactions, to a variety of collaborative arrangements. In addition to this influx of corporate capital, biotechnology companies have seen a significant influx of venture capital, as investors invest in new science and technology that they believe have potential in the clinic. This Kalorama Information report, Recent Biotech Funding Deals and Partnerships, attempts to provide clarity on the phenomenon. The report analyzes the recent, current and potential landscape for investing in the biotechnology sector. Included in the report's coverage are the following data points 56 Key Biotech Deals Analyzed: Financial Details and Therapeutic Potential Venture Capital Dollar Trends, Overall Dollars Invested 2009-2013 (in US billions) Health Care as a Percentage of Total Venture Investment, 2009-2012 (in US billions) Biotech Companies Raising Series A Dollars, 2009-2012, Greater than $2 Million Number of Biotech Series A Companies by Indication Oncology, Platform Discovery, Diagnostics, CNS, Autoimmune) Biotech Total Deal Value, 2005-2012 IPO Statistics Personalized Medicine Disclosed M&A Number of Deals by Focus, 2010-2013 Analyzed are both venture and corporate capital funding efforts. In addition, the report looks at other collaborative approaches, including licensing, joint ventures and partnerships aimed at moving product candidates into the market place as approved therapies, especially if they address unmet medical needs. This report also reviews the nature and direction of funding trends, and reviews the important role that investments play in moving technology into the market place. The report profiles several biotechnology sector companies and the deals that they were involved in from 2011 to 2014. Some of the companies and transactions profiled in the report include: Alkermes, Boston Biomedical, Dicerna Pharmaceuticals, immatics biotechnologies, Micromet, Reata Pharmaceuticals, UCB and Xoma. The information presented in this report is the result of data gathered from company product literature and other corporate brochures and documents, as well as information found in the scientific and trade press. In addition, interviews were conducted with executives and analysts. Table of Content 1.0 EXECUTIVE SUMMARY 1.1 Key Findings Recent Biotech Funding, Deals and Partnerships (From Slideshare) Page 1/12
  2. 2. ReportLinker Find Industry reports, Company profiles and Market Statistics >> Get this Report Now by email! 1.2 Methodology 2.0 INTRODUCTION 2.1 Reason for the Report 2.1.1 Why Investing Is Important 2.1.2 Beyond the Seed Stage 2.1.3 Identify Value Drivers 3.0 TRENDS AND EXPECTATIONS 3.1 Corporate Venture Capital Spurs M&A Activity 3.2 Licensing Deals to Grow 3.3 Venture Capital's Strong Outlook 3.4 Therapeutic Areas of Focus 3.4.1 The Outcomes Push 3.5 In Need of New Strategies 3.5.1 Modeling Potential Success 3.5.2 Crowdfunding 3.5.2.1 A Lifeline 4.0 GROWTH THROUGH SOPHISTICATED COLLABORATIONS 4.1 Determining Product Value 4.1.1 Quantifiable Issues 4.1.2 Revolutionary Value 4.1.3 Global Value 4.2 Changing Roles and Market Landscapes 5.0 VENTURE CAPITAL VS. CORPORATE CAPITAL 5.1 New Fundraising Vistas 5.2 Venture Arms with a Strategy 5.3 Corporate Capital Fundamentals 6.0 INVESTMENT DOLLAR TRENDS 6.1 Annual Numbers 6.1.1 Trends in 2013 6.1.2 Trends in 2012 6.1.3 Trends in 2011 6.1.4 Trends in 2010 6.1.5 Trends in 2009 6.2 Personalized Medicine 7.0 KEY DEALS 7.1 Ablynx NV Description of Deal Size Agreement Type Details Therapeutic Background and Potential 7.2 Acetylon Pharmaceuticals Inc. Description of Deal Size Agreement Type Details Therapeutic Background and Potential 7.3 AC Immune SA Recent Biotech Funding, Deals and Partnerships (From Slideshare) Page 2/12
  3. 3. ReportLinker Find Industry reports, Company profiles and Market Statistics >> Get this Report Now by email! Description of Deal Size Agreement Type Details Therapeutic Background and Potential 7.4 Adimab Description of Deal Size Agreement Type Details Therapeutic Background and Potential 7.5 Aileron Therapeutics Inc. Description of Deal Size Agreement Type Details Therapeutic Background and Potential 7.6 Algeta ASA Description of Deal Size Agreement Type Details Therapeutic Background and Potential 7.7 Alios BioPharma Inc. Description of Deal Size Agreement Type Details Therapeutic Background and Potential 7.8 Alkermes Description of Deal Size Agreement Type Details Therapeutic Background and Potential 7.9 Alnylam Pharmaceuticals Description of Deal Size Agreement Type Details Therapeutic Background and Potential 7.10 Amylin Pharmaceuticals Description of Deal Size Agreement Type Details Therapeutic Background and Potential 7.11 Ardea Biosciences Recent Biotech Funding, Deals and Partnerships (From Slideshare) Page 3/12
  4. 4. ReportLinker Find Industry reports, Company profiles and Market Statistics >> Get this Report Now by email! Description of Deal Size Agreement Type Details Therapeutic Background and Potential 7.12 Atara Biotherapeutics Description of Deal Size Agreement Type Details Therapeutic Background and Potential 7.13 Avila Therapeutics Description of Deal Size Agreement Type Details Therapeutic Background and Potential 7.14 Boston Biomedical Description of Deal Size Agreement Type Details Therapeutic Background and Potential 7.15 Cellectis Description of Deal Size Agreement Type Details Therapeutic Background and Potential 7.16 Clarus Ventures Description of Deal Size Agreement Type Details Therapeutic Background and Potential 7.17 CoStim Pharmaceuticals Description of Deal Size Agreement Type Details Therapeutic Background and Potential 7.18 Covagen AG Description of Deal Size Agreement Type Details Therapeutic Background and Potential 7.19 Dicerna Pharmaceuticals Inc. Recent Biotech Funding, Deals and Partnerships (From Slideshare) Page 4/12
  5. 5. ReportLinker Find Industry reports, Company profiles and Market Statistics >> Get this Report Now by email! Description of Deal Size Agreement Type Details Therapeutic Background and Potential 7.20 Editas Medicine Description of Deal Size Agreement Type Details Therapeutic Background and Potential 7.21 Enanta Pharmaceuticals Inc. Description of Deal Size Agreement Type Details Therapeutic Background and Potential 7.22 Endocyte Inc. Description of Deal Size Agreement Type Details Therapeutic Background and Potential 7.23 Evotec AG Description of Deal Size Agreement Type Details Therapeutic Background and Potential 7.24 Forma Therapeutics Description of Deal Size Agreement Type Details Therapeutic Background and Potential 7.25 Galapagos NV Description of Deal Size Agreement Type Details Therapeutic Background and Potential 7.26 Gemin X Pharmaceuticals Description of Deal Size Agreement Type Details Therapeutic Background and Potential 7.27 Genmab Recent Biotech Funding, Deals and Partnerships (From Slideshare) Page 5/12
  6. 6. ReportLinker Find Industry reports, Company profiles and Market Statistics >> Get this Report Now by email! Description of Deal Size Agreement Type Details Therapeutic Background and Potential 7.28 GlaxoSmithKline Description of Deal Size Agreement Type Details Therapeutic Background and Potential 7.29 Human Genome Sciences Description of Deal Size Agreement Type Details Therapeutic Background and Potential 7.30 immatics Biotechnologies GmbH Description of Deal Size Agreement Type Details Therapeutic Background and Potential 7.31 Inhibitex Description of Deal Size Agreement Type Details Therapeutic Background and Potential 7.32 Inhibrx Description of Deal Size Agreement Type Details Therapeutic Background and Potential 7.33 Isis Pharmaceuticals Inc. Description of Deal Size Agreement Type Details Therapeutic Background and Potential 7.34 Juno Therapeutics Description of Deal Size Agreement Type Details Therapeutic Background and Potential 7.35 Macrogenics Inc. Recent Biotech Funding, Deals and Partnerships (From Slideshare) Page 6/12
  7. 7. ReportLinker Find Industry reports, Company profiles and Market Statistics >> Get this Report Now by email! Description of Deal Size Agreement Type Details Therapeutic Background and Potential 7.36 Mannkind Corp. Description of Deal Size Agreement Type Details Therapeutic Background and Potential 7.37 Medigene AG Description of Deal Size Agreement Type Details Therapeutic Background and Potential 7.38 Melinta Therapeutics Description of Deal Size Agreement Type Details Therapeutic Background and Potential 7.39 Merck Description of Deal Size Agreement Type Details Therapeutic Background and Potential 7.40 Mesoblast Ltd. Description of Deal Size Agreement Type Details Therapeutic Background and Potential 7.41 Micromet AG Description of Deal Size Agreement Type Details Therapeutic Background and Potential 7.42 Moderna Therapeutics Inc. Description of Deal Size Agreement Type Details Therapeutic Background and Potential 7.43 OncoMed Pharmaceuticals Inc. Recent Biotech Funding, Deals and Partnerships (From Slideshare) Page 7/12
  8. 8. ReportLinker Find Industry reports, Company profiles and Market Statistics >> Get this Report Now by email! Description of Deal Size Agreement Type Details Therapeutic Background and Potential 7.44 Onyx Pharmaceuticals Inc. Description of Deal Size Agreement Type Details Therapeutic Background and Potential 7.45 Otonomy Inc. Description of Deal Size Agreement Type Details Therapeutic Background and Potential 7.46 Pharmasset Description of Deal Size Agreement Type Details Therapeutic Background and Potential 7.47 Plexxikon Inc. Description of Deal Size Agreement Type Details Therapeutic Background and Potential 7.48 Reata Pharmaceuticals Description of Deal Size Agreement Type Details Therapeutic Background and Potential 7.49 Royalty Pharma Description of Deal Size Agreement Type Details Therapeutic Background and Potential 7.50 Seattle Genetics Inc. Description of Deal Size Agreement Type Details Therapeutic Background and Potential 7.51 Sutro Biopharma Inc. Recent Biotech Funding, Deals and Partnerships (From Slideshare) Page 8/12
  9. 9. ReportLinker Find Industry reports, Company profiles and Market Statistics >> Get this Report Now by email! Description of Deal Size Agreement Type Details Therapeutic Background and Potential 7.52 Thesan Pharmaceuticals Inc. Description of Deal Size Agreement Type Details Therapeutic Background and Potential 7.53 UCB Inc. Description of Deal Size Agreement Type Details Therapeutic Background and Potential 7.54 Voyager Therapeutics Description of Deal Size Agreement Type Details Therapeutic Background and Potential 7.55 Xenon Pharmaceuticals Inc. Description of Deal Size Agreement Type Details Therapeutic Background and Potential 7.56 Xoma Corp. Description of Deal Size Agreement Type Details LIST OF EXHIBITS 1.0 EXECUTIVE SUMMARY Summary Exhibit: Biotechnology Investment Dollars, 2012 and 2013 ($ millions) 6.0 INVESTMENT DOLLAR TRENDS Exhibit 1: Venture Capital Dollar Trends, Overall Dollars Invested 2009-2013 Exhibit 2: Venture Capital Dollar Trends, Overall Dollars Invested 2009-2013 Exhibit 3: Venture Capital Dollar Trends, Biotechnology Dollars Invested 2009-2013 Exhibit 4: Venture Capital Dollar Trends, Biotechnology Dollars Invested 2009-2013 Exhibit 5: Breakdown of Overall and Biotech Venture Capital Dollars, Billions of Dollars US Invested in 2013 Exhibit 6: Venture Capital Dollar Trends, Biotechnology Dollars Invested by Quarter, 2009-2013 Exhibit 7: Health Care as a Percentage of Total Venture Investment, 2009-2012 Exhibit 8: Biotech Companies Raising Series A Dollars, 2009-2012, Greater than $2 Million Exhibit 9: Number of Biotech Series A Companies by Indication, 2009, Raising More than $2 Million Exhibit 10: Number of Biotech Series A Companies by Indication, 2010, Raising More Than $2 Million Recent Biotech Funding, Deals and Partnerships (From Slideshare) Page 9/12
  10. 10. ReportLinker Find Industry reports, Company profiles and Market Statistics >> Get this Report Now by email! Exhibit 11: Number of Biotech Series A Companies by Indication, 2011, Raising More Than $2 Million Exhibit 12: Number of Biotech Series A Companies by Indication, 2012, Raising More Than $2 Million Exhibit 13: Biotech Total Deal Value, 2005-2012, Minimum Two Big Exits Exhibit 14: Personalized Medicine M&A with Disclosed Values, 2010-2013 Exhibit 15: Personalized Medicine Disclosed M&A Number of Deals by Focus, 2010-2013 Exhibit 16: Personalized Medicine Disclosed M&A Deal Value by Focus, 2010-2013 Exhibit 17: Personalized Medicine Financings, 2010-2013 Exhibit 18: Personalized Medicine Financings by Type, Number of Deals, 2010-2013 Exhibit 19: Personalized Medicine Financings by Category, Number of Deals, 2010-2013 Recent Biotech Funding, Deals and Partnerships (From Slideshare) Page 10/12
  11. 11. ReportLinker Find Industry reports, Company profiles and Market Statistics >> Get this Report Now by email! Fax Order Form To place an order via fax simply print this form, fill in the information below and fax the completed form to: Europe, Middle East and Africa : + 33 4 37 37 15 56 Asia, Oceania and America : + 1 (805) 617 17 93 If you have any questions please visit http://www.reportlinker.com/notify/contact Order Information Please verify that the product information is correct and select the format(s) you require. Product Formats Please select the product formats and the quantity you require. Contact Information Please enter all the information below in BLOCK CAPITALS Title: Mr Mrs Dr Miss Ms Prof First Name: _____________________________ Last Name: __________________________________ Email Address: __________________________________________________________________________ Job Title: __________________________________________________________________________ Organization: __________________________________________________________________________ Address: __________________________________________________________________________ City: __________________________________________________________________________ Postal / Zip Code: __________________________________________________________________________ Country: __________________________________________________________________________ Phone Number: __________________________________________________________________________ Fax Number: __________________________________________________________________________ Recent Biotech Funding, Deals and Partnerships 1 User License--USD 4 500.00 Quantity: _____ 1-5 User License--USD 4 612.50 Quantity: _____ Global Site--USD 9 000.00 Quantity: _____ Recent Biotech Funding, Deals and Partnerships (From Slideshare) Page 11/12
  12. 12. ReportLinker Find Industry reports, Company profiles and Market Statistics >> Get this Report Now by email! Payment Information Please indicate the payment method, you would like to use by selecting the appropriate box. Payment by credit card Card Number: ______________________________________________ Expiry Date __________ / _________ CVV Number _____________________ Card Type (ex: Visa, Amex…) _________________________________ Payment by wire transfer Crédit Mutuel RIB : 10278 07314 00020257701 89 BIC : CMCIFR2A IBAN : FR76 1027 8073 1400 0202 5770 189 Payment by check UBIQUICK SAS 16 rue Grenette – 69002 LYON, FRANCE Please note that by ordering from Reportlinker you are agreeing to our Terms and Conditions at http://www.reportlinker.com/index/terms Please fax this form to: Europe, Middle East and Africa : + 33 4 37 37 15 56 Asia, Oceania and America : + 1 (805) 617 17 93 Customer signature:   Recent Biotech Funding, Deals and Partnerships (From Slideshare) Page 12/12

×